… NO-donating NSAIDs (NO-NSAIDs) possess a traditional … modulate the NO-releasing rate
and targeting capability of NO-… has the risk of the rapid bursting of toxic agents, such as nitrates…

… Critical thiols that control cancer cellular functions might be … the heme-iron-catalyzed reduction
of nitrite with H2S [11]. This … -NSAIDs) is one important strategy to minimize NSAIDs side …

… , ester nitrate and S-nitrosothiol are the main functional groups … This study showed that this
new NSAIDs/NO-donor hybrid has … , the treatment in vivo with complex non-bound NO did not …

… -aspirins has been queried. Moreover, different isomers exhibit … , NO-NSAIDs may also
have roles in cancer treatment or … both in vivo and in vitro models of leukemia, ovarian cancer, …

… cancer, NPB based on chlorambucil, a PB analogue, was synthesized and the effects in vitro
and in vivo … It is known that a part of nitrite ions released from the NO-donor compound are …

… NO-donating NSAID prodrugs (NO-NSAIDs) have been the focus of extensive clinical and
preclinical studies in inflammation and cancer chemoprevention and therapy: a … functions and …

… effective approach in cancer prevention and treatment supporting, … Bacterial features and
balanced microbiome are relatively … NO-NSAIDs and cGMP PDE were reported to have positive …

… the context of cancer prevention and supportive treatment, as … capabilities and can trigger
oxidative stress-induced cancer … , such as: NO-NSAIDs (hybrid nitrate NSAIDs), cGMP PDE (…

… were potentiated by NO generated by the NO-donor DETA/NO. Bioavailability … vivo. A final
comparison of VL-102 with YC-1, in the presence and absence of a related NO-donor, DEA/NO…

… effects on breast cancer prevention. Future studies are needed to test the botanicals in vivo
and … LicA is also a Michael acceptor, but does not have the self-cyclizing capability. LicA has …